Related Experiment Video
Updated: Jul 11, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and
Madison Fraser1, Nagashree Seetharamu2, Matthew Diamond2
1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hofstra University, Hempstead, NY, USA.
Abstract:
Aberrant c-MET (Mesenchymal-Epithelial Transition) signaling contributes to cancer cell development, proliferation, and metastases of non-small cell lung cancer (NSCLC). MET exon 14 (METex14) skipping mutation is noted in approximately 4% of NSCLC cases and is targetable with the recently approved tyrosine kinase inhibitors capmatinib and tepotinib. Capmatinib, the focus of this review article, is a highly selective MET inhibitor approved for use in patients with METex14 mutated NSCLC. In this review, we discuss cMET as a target, the pharmacology of capmatinib, key trials of capmatinib in MET-altered lung cancer, and toxicity profile. We highlight some ongoing capmatinib clinical trials that expand their role to other subsets of patients, especially those with EGFR mutations, who develop MET alterations as a resistance pathway. We further provide our perspective on the management of METex14 NSCLC, strategies for sequencing agents, and toxicity management.
Insights
Capmatinib effectively treats non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. This review covers capmatinib
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Aberrant c-MET signaling drives non-small cell lung cancer (NSCLC) progression and metastasis.
- MET exon 14 (METex14) skipping mutations occur in ~4% of NSCLC cases, representing a targetable oncogenic driver.
- Capmatinib is a selective MET inhibitor approved for METex14-mutated NSCLC.
Purpose of the Study:
- To review the role of c-MET as a therapeutic target in NSCLC.
- To discuss the pharmacology, clinical trials, and toxicity of capmatinib.
- To provide insights into managing METex14 NSCLC and emerging therapeutic strategies.
Main Methods:
- Literature review of preclinical and clinical studies on capmatinib.
- Analysis of key clinical trial data for capmatinib efficacy and safety.
- Discussion of ongoing trials and future directions in MET-targeted therapy.
Main Results:
- Capmatinib demonstrates significant efficacy in patients with METex14-mutated NSCLC.
- The drug's pharmacology supports its targeted action against MET.
- Ongoing trials explore capmatinib in combination therapies and resistance settings, including EGFR-mutated NSCLC.
Conclusions:
- Capmatinib is a crucial targeted therapy for METex14-mutated NSCLC.
- Understanding capmatinib's role in various clinical scenarios, including resistance mechanisms, is essential.
- Future strategies involve optimizing sequencing, combination therapies, and toxicity management for MET-altered lung cancers.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Kaplan-Meier Approach